A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

Author： Burris Howard   Jones Suzanne   Williams Daphne   Kathman Steven   Hodge Jeffrey   Pandite Lini   Ho Peter   Boerner Scott   LoRusso Patricia  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.3, 2011-06, pp. : 467-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

By Hilgers Werner   Faivre Sandrine   Chieze Stéphanie   Alexandre Jérôme   Lokiec François   Goldwasser François   Raymond Eric   Kahatt Carmen   Taamma Abdelkrim   Weems Garry   MacDonald John   Misset Jean-Louis   Cvitkovic Esteban  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 311-319

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors

By Kalmadi S.   Davis M.   Dowlati A.   O’Keefe S.   Cline-Burkhardt M.   Pelley R.   Borden E.   Dreicer R.   Bukowski R.   Mekhail T.  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 211-216

Springer Publishing Company

Access to resources Recommend Favorite

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

By Hollebecque A.   Deutsch E.   Massard C.   Gomez-Roca C.   Bahleda R.   Ribrag V.   Bourgier C.   Lazar V.   Lacroix L.   Gazzah A.   Varga A.   Baere T.   Beier F.   Kroesser S.   Trang K.   Zenke F.   Klevesath M.   Soria Jean-Charles  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1530-1538

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

By Advani Ranjana   Lum Bert   Fisher George   Halsey Joanne   Geary Richard   Holmlund Jon   Kwoh T.   Dorr F.   Sikic Branimir  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 467-477

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

By Chen Eric   Batist Gerald   Siu Lillian   Bangash Naeema   Maclean Martha   McIntosh Lynn   Miller Wilson   Oza Amit   Lathia Chetan   Petrenciuc Oana   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 5, 2005-10 ,pp. : 455-465

Springer Publishing Company

Access to resources Recommend Favorite